JP2023522615A - E型肝炎の治療のための二環式及び単環式ヌクレオシド類似体 - Google Patents

E型肝炎の治療のための二環式及び単環式ヌクレオシド類似体 Download PDF

Info

Publication number
JP2023522615A
JP2023522615A JP2022562424A JP2022562424A JP2023522615A JP 2023522615 A JP2023522615 A JP 2023522615A JP 2022562424 A JP2022562424 A JP 2022562424A JP 2022562424 A JP2022562424 A JP 2022562424A JP 2023522615 A JP2023522615 A JP 2023522615A
Authority
JP
Japan
Prior art keywords
compound
compounds
mmol
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522615A5 (cg-RX-API-DMAC7.html
Inventor
ヨンカーズ,ティム,ヒューゴ,マリア
ポーウェルス,フレデリック
デビン,ヤニック
Original Assignee
ヤンセン ファーマシューティカルズ,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカルズ,インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ,インコーポレーテッド
Publication of JP2023522615A publication Critical patent/JP2023522615A/ja
Publication of JP2023522615A5 publication Critical patent/JP2023522615A5/ja
Priority to JP2026038584A priority Critical patent/JP2026120528A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2022562424A 2020-04-14 2021-04-13 E型肝炎の治療のための二環式及び単環式ヌクレオシド類似体 Pending JP2023522615A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026038584A JP2026120528A (ja) 2020-04-14 2026-03-11 E型肝炎の治療のための二環式及び単環式ヌクレオシド類似体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20169480 2020-04-14
EP20169480.9 2020-04-14
PCT/EP2021/059504 WO2021209419A1 (en) 2020-04-14 2021-04-13 Bi- and monocyclic nucleoside analogs for treatment of hepatitis e

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026038584A Division JP2026120528A (ja) 2020-04-14 2026-03-11 E型肝炎の治療のための二環式及び単環式ヌクレオシド類似体

Publications (2)

Publication Number Publication Date
JP2023522615A true JP2023522615A (ja) 2023-05-31
JP2023522615A5 JP2023522615A5 (cg-RX-API-DMAC7.html) 2024-04-18

Family

ID=70289599

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562424A Pending JP2023522615A (ja) 2020-04-14 2021-04-13 E型肝炎の治療のための二環式及び単環式ヌクレオシド類似体
JP2026038584A Pending JP2026120528A (ja) 2020-04-14 2026-03-11 E型肝炎の治療のための二環式及び単環式ヌクレオシド類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026038584A Pending JP2026120528A (ja) 2020-04-14 2026-03-11 E型肝炎の治療のための二環式及び単環式ヌクレオシド類似体

Country Status (15)

Country Link
EP (1) EP4135715B1 (cg-RX-API-DMAC7.html)
JP (2) JP2023522615A (cg-RX-API-DMAC7.html)
KR (1) KR20230002592A (cg-RX-API-DMAC7.html)
CN (1) CN115515603A (cg-RX-API-DMAC7.html)
AR (1) AR121836A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021255809B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022020825A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174790A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002804A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982564T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022012904A (cg-RX-API-DMAC7.html)
PE (1) PE20230386A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552679A1 (cg-RX-API-DMAC7.html)
UY (1) UY39172A (cg-RX-API-DMAC7.html)
WO (1) WO2021209419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086592A2 (en) * 2022-10-17 2024-04-25 Emory Unversity 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2025014360A1 (en) * 2023-07-07 2025-01-16 Erasmus University Medical Center Rotterdam Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519784A (ja) * 2014-06-24 2017-07-20 アリオス バイオファーマ インク. 置換ヌクレオシド、ヌクレオチドおよびその類似体
US20170348343A1 (en) * 2016-06-03 2017-12-07 Gilead Pharmasset Llc Methods of treating hepatitis e viral infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952714T3 (es) * 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
SG11201610597QA (en) * 2014-06-24 2017-01-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519784A (ja) * 2014-06-24 2017-07-20 アリオス バイオファーマ インク. 置換ヌクレオシド、ヌクレオチドおよびその類似体
US20170348343A1 (en) * 2016-06-03 2017-12-07 Gilead Pharmasset Llc Methods of treating hepatitis e viral infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GASTROENTEROLOGY, vol. 150, JPN6025016427, 2016, pages 82 - 85, ISSN: 0005583714 *

Also Published As

Publication number Publication date
CA3174790A1 (en) 2021-10-21
US20230310481A1 (en) 2023-10-05
EP4135715A1 (en) 2023-02-22
CL2022002804A1 (es) 2023-03-31
AU2021255809B2 (en) 2026-08-06
CN115515603A (zh) 2022-12-23
PH12022552679A1 (en) 2024-04-22
BR112022020825A2 (pt) 2022-11-29
EP4135715B1 (en) 2024-05-08
ES2982564T3 (es) 2024-10-16
MX2022012904A (es) 2023-01-24
AU2021255809A1 (en) 2022-12-15
PE20230386A1 (es) 2023-03-06
UY39172A (es) 2021-10-29
EP4135715C0 (en) 2024-05-08
WO2021209419A1 (en) 2021-10-21
AR121836A1 (es) 2022-07-13
KR20230002592A (ko) 2023-01-05
JP2026120528A (ja) 2026-07-22

Similar Documents

Publication Publication Date Title
US11267825B2 (en) Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV)
US20110171192A1 (en) Substituted amine derivative and medicinal composition comprising same as the active ingredient
BR112015020472B1 (pt) composto de fosforamidato de nucleosídeo, composição farmacêutica e uso do mesmo
EA032239B1 (ru) Способы лечения вирусных инфекций filoviridae
JP2022506337A (ja) B型肝炎ウイルス(hbv)に対して活性を有する6,7-ジヒドロ-4h-ピラゾロ[1,5-a]ピラジンインドール-2-カルボキサミド
KR20100020484A (ko) 헤테로아릴 치환된 티아졸 그리고 항-바이러스제로서의 그들의 사용
JP2016538252A (ja) 置換された(s)−(2r,3r,5r)−3−ヒドロキシ−(5−ピリミジン−1−イル)テトラヒドロフラン−2−イルメチルアリールホスホロアミデート
RU2299202C2 (ru) N-фениларилсульфонамид, фармацевтическая композиция, содержащая указанное соединение в качестве активного ингредиента, соединение, являющееся промежуточным в синтезе указанного соединения, и способ его получения
JP2022521081A (ja) Hbv感染若しくはhbv誘導性疾患の治療において有用なアミド誘導体
EP4135715B1 (en) Bi- and monocyclic nucleoside analogs for treatment of hepatitis e
CN115974855A (zh) Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途
CN116102553A (zh) 一种芳香稠环亚胺类化合物及其制备方法和应用
JP2023522612A (ja) E型肝炎の治療のためのスピロ環式ヌクレオシド類似体
HK40085931A (en) Bi- and monocyclic nucleoside analogs for treatment of hepatitis e
HK40088561B (en) Bi- and monocyclic nucleoside analogs for treatment of hepatitis e
HK40088561A (en) Bi- and monocyclic nucleoside analogs for treatment of hepatitis e
OA21046A (en) BI- and monocyclic nucleoside analogs for treatment of hepatitis E.
JP2023521425A (ja) E型肝炎の治療のためのアルキニルヌクレオシド類似体
HK40085110A (en) Spirocyclic nucleoside analogues for the treatment of hepatitis e
CN118005694B (zh) 一种环状核苷类似物及其制备方法和应用
CN114127078B (zh) 杂化合物及其使用方法
HK40090491A (en) Alkynyl nucleoside analogs for treatment of hepatitis e
CN117126162A (zh) 多取代杂环类化合物及其制备方法和应用
JP2001114689A (ja) チロシン脱リン酸化酵素阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251111